PMC:6019327 / 284090-285338 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6019327","sourcedb":"PMC","sourceid":"6019327","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6019327","text":"In considering these consensus recommendations, it is worth commenting that some patients who have multiple stroke risk factors are highly motivated to discontinue systemic anticoagulation and are willing to accept a possible increased risk of stroke. It is for these patients that we recommend that some type of continuous monitoring be performed to screen for silent AF at regular intervals as long as they remain untreated with systemic anticoagulation. A survey of the writing group members shows that 77% continue anticoagulation indefinitely in patients who have undergone AF ablation and who have a CHA2DS2-VASc score of 2 or greater. It is possible that the outcomes of the CABANA and Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST) (NCT01288352) will help clarify this issue. In selected patients with ECG, evidence of AF control, and diligent follow-up for AF recurrences, 23% of the writing group members indicated that they would consider discontinuing anticoagulation after a conversation with the patients in which risks and benefits were discussed. This survey also shows that only 1 writing committee member (2%) routinely discontinues anticoagulation in all patients following AF ablation who are AF-free.","tracks":[]}